But as venture outlays fall, a recent spurt of layoffs has clouded outlook By Robert Weisman Globe Staff Massachusetts continued to expand its biopharma workforce in research labs and manufacturing plantslast year even as venture capital investment dwindled and fewer biotech companies went public. Overall employment in the sector — a bellwether of the state’s […]
President Joe Biden is infusing billions of dollars into a new, biotech-focused initiative, and it’s likely to have immediate ramifications for New England. Boston has long been a hotbed for pharmaceuticals in addition to upstart biotechs. But the White House is expanding the definition of what a “bioeconomy” could be, looking beyond drugmaking to other applications of […]
by Lucia Maffei / via The Business Journals Two biotech startups from the Bay State, two from Canada and one from California will take part in MassBio’s first installment of its accelerator program MassBioDrive, culminating in an in-person Demo Day and cash stipends for each venture. The Massachusetts Biotechnology Council, an industry group better known […]
by Rowan Walrath / via The Boston Business Journal For the second straight year, the amount of venture capital that was poured into Massachusetts-based life sciences companies has eclipsed all previous fundraising records, ringing in at $13.66 billion in 2021. According to a report from the Massachusetts Biotechnology Council, an industry group better known as […]
by Catherine Carlock / via The Boston Globe A Waltham lab and office building that started construction in 2019 without any tenants committed has landed leases from two biotech companies. Seqirus, a global influenza vaccine maker with a local research and development arm in Cambridge, and ElevateBio BaseCamp, the Waltham research and development and manufacturing arm […]
France-based pharmaceutical company Ipsen recently announced that it will be relocating its research and development facility from Milford to East Cambridge. Following the trend of big biotech and pharma companies planning the move to Cambridge, Ipsen signed a long-term lease for 62,600 square feet of lab and office space at 650 Kendall Street in Kendall Square. […]
There are currently 2.5 million square feet under construction in the city of Cambridge. From Central Square to East Cambridge, commercial real estate development is thriving. A great deal of this construction consists of lab space for tech and pharmaceutical companies. One reason for this is the Commonwealth is looking to take advantage of the talent […]
Epizyme Inc, a Cambridge-based cancer drug company, commenced public trading last Friday. The biotech listed its initial public offering at $15 a share on the Nasdaq, under the ticker symbol “EPZM.” The rapidly-growing oncology company is offering 5.1 million shares, with the IPO expected to raise $88.8 million if all shares are sold. While only […]
